louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02940158: Various Serving Sizes of Lentils on Blood Glucose and Insulin
Official title: The Effect of Various Serving Sizes of Lentils and Other Starchy Meals on Post Prandial Blood Glucose Response and Insulin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: lentils
diabetes
glycemia
insulin
glucose
Lead sponsor: University of Guelph
Sponsor class: OTHER
Collaborators: name: Agriculture and Agri-Food Canada
name: Saskatchewan Pulse Growers
First posted: 2016-10-20
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The purpose of this study is to assess the effects of consuming either 1/2 or 1/4 cup servings of lentils on post-prandial blood glucose and insulin as compared to 4 types of starchy foods (corn, macaroni, white potato, white rice).

Detailed description: Eligible participants will undergo a total of 6 study visits. During each visit, a fasted blood sample will be taken by fingerprick, and approximately 500 µL of blood will be dripped into a collection tube. The participant will then consume a meal of either: two types of lentils, corn, macaroni, white rice, or white potato. All study days will be randomized. Each meal will be served in either 1/4 or 1/2 cup servings depending on the study block. Six more blood samples will be taken by fingerprick at 15, 30, 45, 60, 90 and 120 minutes after the beginning of the meal.

Eligibility criteria: Inclusion Criteria

* Healthy men and women
* Age 18-40 years
* Body mass index (BMI) 20-30 kg/m2

Exclusion Criteria:

* Tobacco use
* Pregnant or breastfeeding
* Fasting blood glucose ≥ 7.0 mmol/L
* Two hour blood glucose ≥ 11.1 mmol/L after consuming 75g glucose drink (Oral Glucose Tolerance Test beverage)
* Any major medical condition including a history of AIDS or hepatitis
* Medical or surgical event requiring hospitalization within 3 months of randomization
* Any medications except a stable dose (3 months) of oral contraceptives, blood pressure or statin medications
* Blood pressure \>140/90 mm Hg
* Natural health products (NHPs) used for glycemic control
* Probiotic supplements
* Dietary fibre supplements
* Consumption of \>4 servings of pulses per week
* Food allergy or non-food life threatening allergy
* Shift workers
* Alcohol consumption \>14 drinks/week or \>4 drinks/sitting
* Recent or intended significant weight loss or gain (\>4 kg in previous 3 months)
* Elite athletes

Primary outcomes:
measure: Postprandial Blood Glucose
timeFrame: 2 hours Postprandial
measure: Postprandial Blood Insulin
timeFrame: 2 hours postprandial
Secondary outcomes:
Other outcomes:
Locations:
city: Guelph
country: Canada
facility: Human Nutraceutical Research Unit
state: Ontario
Study officials:
References:
Clinical trial NCT05333796: The Effect of Back Muscles Activation on Idiopathic Scoliosis Using Surface Electromyography
Official title: The Effect of Back Muscles Activation on Idiopathic Scoliosis Using Surface Electromyography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Idiopathic Scoliosis
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2022-04-19
Enrollment: 39
Sex: ALL
Minimum age (years): 5
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effect of back muscle activations on idiopathic scoliosis

Detailed description: * Design: Prospective study
* Setting: hospital rehabilitation department
* Intervention: Participants were asked to walk with a surface electromyography(EMG) attached to their back muscles. After repeating the same process with different leg lengths discrepancy (0cm, 0.5cm, 1cm), participants are compared the main outcome measures.
* Main outcome measures: surface electromyography(EMG)

Eligibility criteria: Inclusion Criteria:

* Healthy children (5 to 12 years old)

Exclusion Criteria:

* Children with leg length discrepancy over 0.5cm
* Children complaining of acute low back pain
* Children with spinal scoliosis
* Children with cerebral palsy, muscle paralysis, polio, congenital spinal abnormalities
* Children who underwent spinal surgery

Primary outcomes:
measure: surface electromyography
timeFrame: 20 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi-do
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Jusuk Ryu, M.D. PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01838096: Alumina Matrix Composite Ceramic Bearing Total Hip Arthroplasty in Patients Younger Than 30 Years
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Advanced Hip Disease
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
Collaborators: name: CeramTec GmbH
First posted: 2013-04-23
Enrollment: 92
Sex: ALL
Minimum age (years): 15
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will evaluate clinical outcome on patients who undergo cementless 4th generation ceramic (BIOLOX®delta, CeramTec GmbH, Plochingen, Germany) on ceramic (CoC) bearing total hip aArthroplasty ("THA") in patients younger than 30 years.


Eligibility criteria: Inclusion Criteria:

* younger than 30 years
* advanced hip disease

Exclusion Criteria:

* older than 30 years

Primary outcomes:
measure: survival rate of 4th generation ceramic-on-ceramic THA
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Kyung-Hoi Koo, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lee YK, Kim KC, Yoon BH, Kim TY, Ha YC, Koo KH. Cementless total hip arthroplasty with delta-on-delta ceramic bearing in patients younger than 30 years. Hip Int. 2021 Mar;31(2):181-185. doi: 10.1177/1120700019889592. Epub 2019 Nov 25.
Clinical trial NCT06482996: General Anesthesia on Blood Pressure and Intraocular Pressure in Geriatric Patients Undergoing Cataract Surgery
Official title: the Impact of General Anesthesia on Blood Pressure and Intraocular Pressure in Geriatric Patients Undergoing Cataract Surgery
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cataract
Keywords: Cataract surgery
Frailty
Lead sponsor: Umraniye Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2024-07-01
Enrollment: 80
Sex: ALL
Minimum age (years): 65
Maximum age (years): 85
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This prospective randomized controlled double-blind study included a total of 80 ASA I-III patients aged 65-85 years undergoing cataract surgery under general anesthesia. Randomization Patients were randomly divided into two groups with frailty score as non-frail (40 patients) and pre-frail/frail (40 patients) by closed envelope method.

Brief summary: The primary aim of the study is to investigate the correlation between preoperative hemodynamics and frailty scores in patients undergoing cataract surgery under general anesthesia. The secondary objective is to explore the relationship between preoperative and postoperative intraocular pressure changes and frailty scores.

Detailed description: Cataract stands as a significant cause of vision impairment worldwide, notably prevalent among the elderly. This study aims to explore the changes in intraocular pressure (IOP) and blood pressure under general anesthesia during cataract surgery in frail geriatric patients. The research emphasizes the critical role of frailty assessment in determining surgical risks among elderly surgical patients. It focuses on the hypothesis that frail individuals undergoing cataract surgery under general anesthesia might experience more pronounced effects on IOP and blood pressure during the surgical procedure compared to prefrail counterparts. This study emerges as a crucial step in understanding the impact of preoperative frailty assessment on surgical planning and outcomes.

Eligibility criteria: Inclusion Criteria:

* 65-85 age
* ASA I-III
* cataract surgery with genel anesthesia

Exclusion Criteria:

* cerebrovascular disease,
* mental retardation and psychiatric illness,
* pulmonary infection, history of advanced COPD or respiratory failure,
* EF less than 40%, presence of cardiovascular disease,
* bleeding diathesis,
* renal and hepatic insufficiency,
* presence of diabetes mellitus, diuretic/mannitol users,
* substance abuse
* BMI \>30

Primary outcomes:
measure: intraocular pressure during genel anesthesia
timeFrame: through study completion, an average of 1 day
Secondary outcomes:
measure: hemodynamic data
timeFrame: through study completion, an average of 1 day
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Umraniye Education and Research hospital
Study officials:
References:
Clinical trial NCT00846196: A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects
Official title: A Crossover Study to Assess the Bioequivalence of the Phase III and Commercial Risedronate 35 mg Delayed Release Formulations.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Osteoporosis
Lead sponsor: Warner Chilcott
Sponsor class: INDUSTRY
Collaborators: name: Sanofi
First posted: 2009-02-18
Enrollment: 538
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: Randomized, double-blind, 2-treatment, 2-period, 2-sequence, crossover study, The study will consist of a screening visit, study center admission (preceding Treatment Periods 1 and 2), 2 treatment periods (4 days each), 1 washout period (14 to 17 days separating periods 1 and 2), and exit procedures.


Eligibility criteria: Inclusion Criteria:

* male or female, 18 to 65 years of age
* if female, non-lactating and either surgically sterile or postmenopausal
* body mass index less than or equal to 32 kg/m2 at screening

Exclusion Criteria:

* no use of a bisphosphonate within 1 month
* no history of GI disease
* no use of any medications within 7-14 days prior to scheduled dosing day

Primary outcomes:
measure: Assess the bioequivalence (BE) between the commercial and the Phase III risedronate 35 mg DR formulations.
timeFrame: 72 hours post-dose
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Research Site
state: California
city: Fort Myers
country: United States
facility: Research Site
state: Florida
city: Miramar
country: United States
facility: Research Site
state: Florida
city: Omaha
country: United States
facility: Research Site
state: Nebraska
city: Austin
country: United States
facility: Research site
state: Texas
city: Dallas
country: United States
facility: Research Site
state: Texas
Study officials:
affiliation: Procter and Gamble
name: Chantell Wilson, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01338896: Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations
Official title: A Multicenter, Randomized, Double-blind, Two-way Cross-over Study to Compare the Adhesiveness of Two Different Rotigotine Patch Formulations in Subjects With Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Parkinson's Disease
Keywords: Rotigotine
Neupro
Lead sponsor: UCB Pharma
Sponsor class: INDUSTRY
First posted: 2011-04-20
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The primary objective of the study is to compare the adhesiveness of two different patch formulations of rotigotine using patch size 40 cm2, under the assumption that both patch formulations show similar adhesiveness properties.


Eligibility criteria: Inclusion Criteria:

* Subjects with a diagnosis of idiopathic Parkinson´s disease, and continuous treatment with commercially available rotigotine transdermal patch for at least 3 months, and a stable rotigotine dose including an 8 mg/24 h patch for at least 2 weeks prior to enrollment

Exclusion Criteria:

* Subjects has previously participated in this study, failed to be screened, or has participated in another study with an investigational medicinal product (IMP) or medical device within the last 30 days or is currently participating in such
* Subject with a history of significant skin hypersensitivity to adhesives, other transdermal products or recently unsolved contact dermatitis

Primary outcomes:
measure: The average adhesiveness score of 2 days of 24 hours patch application as rated by the investigator (or designee)
timeFrame: 2 days of 24 hours patch application
Secondary outcomes:
measure: Patch adhesiveness of first treatment day as rated by the investigator (or designee) 24 hours after patch application
timeFrame: after 24 hours of patch application
measure: Patch adhesiveness of second treatment day as rated by the investigator (or designee) 24 hours after patch application
timeFrame: after 24 hour of patch application
Other outcomes:
Locations:
city: Innsbruck
country: Austria
city: Wien
country: Austria
city: Alzenau
country: Germany
city: Berlin
country: Germany
city: Boblingen
country: Germany
city: Bochum
country: Germany
city: Gera
country: Germany
city: Karlstadt
country: Germany
city: Koln
country: Germany
city: Stuttgart
country: Germany
city: Wolfach
country: Germany
city: Blackpool
country: United Kingdom
city: Derby
country: United Kingdom
city: Liverpool
country: United Kingdom
city: Newcastle Upon Tyne
country: United Kingdom
city: Norwich
country: United Kingdom
Study officials:
affiliation: +1 877 822 9493 (UCB)
name: UCB Clinical Trial Call Center
role: STUDY_DIRECTOR
References:
citation: Elshoff JP, Timmermann L, Schmid M, Arth C, Komenda M, Brunnert M, Bauer L. Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulations. Curr Med Res Opin. 2013 Dec;29(12):1657-62. doi: 10.1185/03007995.2013.841666. Epub 2013 Sep 23.
Clinical trial NCT00922896: Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
Official title: A Phase II Trial of Erlotinib in Combination With Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Metastatic Pancreatic Cancer
Keywords: Gemcitabine
Cisplatin
Erlotinib
Lead sponsor: Gyeongsang National University Hospital
Sponsor class: OTHER
Collaborators: name: Dong-A University Hospital
name: Chung-Ang University Hosptial, Chung-Ang University College of Medicine
First posted: 2009-06-17
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.


Eligibility criteria: Inclusion Criteria:

* Age older than 18
* Younger than 75
* ECOG performance status 0 or 1
* Histologically confirmed adenocarcinoma of the pancreas
* Metastatic pancreatic cancer
* No prior chemotherapy for metastatic pancreatic cancer
* A patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in Spiral CT or multidetector CT (MD CT)

Exclusion Criteria:

* A patient with no measurable disease
* A patient who received previous palliative chemotherapy for pancreatic cancer
* A patient with locally advanced pancreatic cancer
* A patient who received adjuvant chemotherapy for pancreatic cancer within 1 year
* A patient with previous active or passive immunotherapy
* A pregnant or lactating patient

Primary outcomes:
measure: To assess the response rate associated with gemcitabine, erlotinib and cisplatin in patients with advanced pancreatic cancer
timeFrame: Clinically assessed every cycle (month) and radiologically assessed every 2 cycles (6 weeks) with CT scan
Secondary outcomes:
Other outcomes:
Locations:
city: Busan
country: Korea, Republic of
facility: Dong-A University Hospital
city: JinJU
country: Korea, Republic of
facility: Gyeongsang Unversity Hospital
city: Seoul
country: Korea, Republic of
facility: Chung-Ang University Hospital
Study officials:
References:
citation: Hwang IG, Jang JS, Oh SY, Lee S, Kwon HC, Lee GW, Go S, Kang MH, Cha YJ, Kang JH. A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. Invest New Drugs. 2012 Dec;30(6):2371-6. doi: 10.1007/s10637-012-9792-z.
Clinical trial NCT05171296: Noninvasive Hemoglobin Monitoring by Spectrophotometry in Blunt Abdominal Trauma Patients for Conservative Management
Official title: Noninvasive Hemoglobin Monitoring by Spectrophotometry (SpHb) in Blunt Abdominal Trauma Patients for Conservative Management
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Intensive Care Unit
Keywords: massimo
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2021-12-28
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients who will be admitted to Ain Shams university hospital - surgical intensive care unit, after blunt abdominal trauma planned for conservation.

Brief summary: We aimed to study the efficacy of Noninvasive Hemoglobin Monitoring by Spectrophotometry in monitoring hemoglobin level in trauma patients for conservative management.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status I to III, of either sex, 18 -80 years of age, non-sedated non-intubated patients who will be admitted to Ain Shams university hospital - surgical intensive care unit, after blunt abdominal trauma planned for conservation.

Exclusion Criteria:

* Patients with fever, hypothermia, history of a neurological, psychiatric, dementia or, who are taking psychotropic drugs Patients with unstable hemodynamic status, and unconscious patients.

Primary outcomes:
measure: accuracy of hemoglobin measured by the noninvasive device.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University hospitals
Study officials:
References:
Clinical trial NCT03297996: Study of Gut Microbiome and Colorectal Tumors
Official title: The Gut Microbiota in Conventional and Serrated Precursors of Colorectal Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Serrated Polyp
Hyperplastic Polyp
Sessile Serrated Adenoma
Colorectal Cancer
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2017-09-29
Enrollment: 540
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: There are no enrollment restrictions based on race or ethnic origins. Vulnerable subjects such as pregnant women and children will not be involved in this study. We will not ask subjects about sensitive topics such as Mental Health, drug/alcohol abuse, or others that fall in this category.

Brief summary: Gut microbiota were assessed in 540 colonoscopy-screened adults by 16S rRNA gene sequencing of stool samples. Investigators compared gut microbiota diversity, overall composition, and normalized taxon abundance among these groups.

Detailed description: Colorectal cancer is a heterogeneous disease arising from at least two precursors-the conventional adenoma (CA) and the serrated polyp. A relationship between the human gut microbiota and colorectal cancer has been shown; however, its relationship to the different early precursors of colorectal cancer is understudied. This study tested, for the first time, the relationship of the gut microbiota to specific colorectal polyp types.

Eligibility criteria: Inclusion Criteria:

* Both men and women who have visited a gastroenterologist or surgeon, aged 18 or older will be included in this study.
* Both men and women residents in the United States, aged 18 or older will be included in this study.

Exclusion Criteria:

* Women who are pregnant will be excluded from participating in this study
* Subjects on ongoing antibiotic therapy will be excluded from participating in this study.

Primary outcomes:
measure: Prevalence and relative abundance of selected fecal microbial taxa
timeFrame: 2 Days
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York University School of Medicine
state: New York
Study officials:
affiliation: NYU Langone Health
name: Jiyoung Ahn, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01585896: Self-Help Group for the Treatment of Hoarding Disorder
Official title: Self-Help Group for the Treatment of Hoarding Disorder
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Hoarding Disorder
Keywords: Hoarding
Compulsive Hoarding
Self-Help
Lead sponsor: University of Miami
Sponsor class: OTHER
First posted: 2012-04-26
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The proposed study aims to investigate the efficacy of a facilitated self-help group for the treatment of hoarding disorder. Eligible participants will take part in a facilitated self-help group. The investigators aim to investigate the effects of a self-help group on hoarding symptoms. The investigators hypothesize that participants will demonstrate decreased hoarding symptoms over time.


Eligibility criteria: Inclusion Criteria:

* clinically relevant symptoms of hoarding disorder

Exclusion Criteria:

* under 18
* psychotic disorders, bipolar disorder, substance abuse or dependence

Primary outcomes:
measure: Hoarding Rating Scale
timeFrame: 13 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Coral Gables
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Kiara R Timpano, PhD
role: PRINCIPAL_INVESTIGATOR
References: